Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
p38 MAP kinase inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:alternativeName |
Doramapimod
|
| gptkbp:CASNumber |
371242-69-2
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Boehringer_Ingelheim
|
| gptkbp:hasMolecularFormula |
C22H18F3N3O2
|
| gptkbp:hasSMILES |
COC1=CC=C(C=C1)C2=NC(=N(C3=CC=C(F)C=C3)C4=CC=CC=C4)C=C2CCO
|
| gptkbp:hasUNII |
1X8F2K0A2V
|
| https://www.w3.org/2000/01/rdf-schema#label |
BIRB 796
|
| gptkbp:investigatedBy |
gptkb:Crohn's_disease
rheumatoid arthritis |
| gptkbp:IUPACName |
2-(4-(4-fluorophenyl)-2-(4-methoxyphenyl)-1H-imidazol-5-yl)ethanol
|
| gptkbp:mechanismOfAction |
inhibits p38 MAP kinase activity
|
| gptkbp:molecularWeight |
413.4 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL121
9933476 |
| gptkbp:target |
gptkb:p38_MAP_kinase
|
| gptkbp:bfsParent |
gptkb:MAPK/p38_pathway
gptkb:MAPK14 gptkb:p38_MAPK gptkb:p38_delta |
| gptkbp:bfsLayer |
7
|